National Cancer Institute®
Last Modified: November 21, 2001
UI - 21262733
AU - Bougeard G; Limacher JM; Martin C; Charbonnier F; Killian A; Delattre O;
TI - Longy M; Jonveaux P; Fricker JP; Stoppa-Lyonnet D; Flaman JM; Frebourg T Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome.
SO - J Med Genet 2001 Apr;38(4):253-7
UI - 21300246
AU - Malkin D
TI - The role of p53 in human cancer.
SO - J Neurooncol 2001 Feb;51(3):231-43
AD - Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada. firstname.lastname@example.org
In the two decades since its original discovery, p53 has found a singularly prominent place in our understanding of human cancer. Although the biochemistry of p53 has been worked out in some detail, our knowledge of the biologic consequences of p53 dysfunction is still quite rudimentary. Over the next several years, it will be important to determine how best to harness the complex properties of p53's ability to induce cellular growth arrest and cell death to generate novel, effective approaches to cancer therapy. Furthermore, a clearer appreciation of the direct interaction of epigenetic factors with p53 will lead to development of strategies to inhibit tumour initiation and progression. The next decade promises to offer exciting opportunities to apply our vast knowledge of this intriguing tumor suppressor to clinical advantage.
UI - 92341381
AU - Li FP; Garber JE; Friend SH; Strong LC; Patenaude AF; Juengst ET; Reilly
TI - PR; Correa P; Fraumeni JF Jr Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals.
SO - J Natl Cancer Inst 1992 Aug 5;84(15):1156-60
AD - Dana-Farber Cancer Institute, Boston, Mass.
UI - 93278969
AU - Evans G
TI - Ethical issues: the geneticist's view point.
SO - Dis Markers 1992 Jul-Aug;10(4):199-203; discussion 211-28
AD - Department of Medical Genetics, St Mary's Hospital, Manchester.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.